What is the carcinoembryonic antigen (CEA) test used for?

What is the CEA Test Used For?

The carcinoembryonic antigen (CEA) test is a blood test used primarily for monitoring colorectal cancer recurrence after curative surgery and for tracking treatment response in metastatic disease—it is NOT used for cancer screening or diagnosis. 1

Primary Clinical Applications

Post-Operative Surveillance in Colorectal Cancer

• Measure CEA every 3 months for the first 3 years after curative resection in patients with stage II or III colorectal cancer who are candidates for further surgery or chemotherapy, as this is when 74–82% of recurrences occur. 1, 2
• Continue CEA monitoring every 6–12 months during years 4–5, then discontinue routine surveillance after year 5 in most patients. 2
• CEA detects 58–64% of all recurrences before other modalities and is the most cost-effective approach for identifying potentially resectable metastases. 2
• Even patients with normal pre-operative CEA should undergo post-operative CEA monitoring, because 41–60% will develop CEA elevation if recurrence occurs. 2, 3

Monitoring Metastatic Disease During Treatment

• Obtain CEA at treatment initiation, then measure every 1–3 months throughout systemic therapy to assess treatment response. 1, 2
• Two consecutive CEA values above baseline indicate disease progression, even without radiographic confirmation. 1, 2
• Interpret rising CEA cautiously during the first 4–6 weeks of new therapy (especially oxaliplatin-based regimens), as spurious early rises are common. 1, 2

Pre-Operative Staging and Prognosis

• Measure CEA pre-operatively to assist in staging and surgical planning; elevated levels (≥5 ng/mL) correlate with poorer prognosis regardless of tumor stage. 1, 3
• Pre-operative CEA ≥5 ng/mL is an independent prognostic variable predicting worse outcomes. 3
• Even CEA levels within the "normal" range (2.1–5.0 ng/mL) predict inferior disease-free survival compared to levels <2.1 ng/mL. 4

What CEA is NOT Used For

Screening and Diagnosis

• CEA should never be used for cancer screening in asymptomatic populations due to insufficient sensitivity and specificity. 1, 2, 5
• CEA cannot diagnose cancer or confirm suspected malignancy because of high false-positive rates in low-prevalence populations. 1, 5
• Benign conditions—including gastritis, peptic ulcer disease, inflammatory bowel disease, liver disease, COPD, and diabetes—can elevate CEA, limiting diagnostic utility. 1, 3

Treatment Decisions

• An elevated CEA alone does not justify starting adjuvant therapy or systemic treatment without radiographic or pathologic confirmation of disease. 1, 2

Interpreting CEA Results

Normal Reference Range

• The standard threshold is 5 ng/mL, though some evidence suggests 10 ng/mL may reduce false positives. 1
• Levels between 2.1–5.0 ng/mL (high-normal) predict worse prognosis than <2.1 ng/mL in colorectal cancer. 4

When CEA is Elevated

• Always confirm an elevated CEA with repeat testing before proceeding with extensive workup. 1, 2
• After confirmation, obtain contrast-enhanced CT of chest, abdomen, and pelvis to identify potentially resectable recurrence or metastatic disease. 1, 3
• For rectal cancer, add contrast-enhanced pelvic MRI to better evaluate local pelvic recurrence. 1

Clinical Impact of CEA-Detected Recurrence

• Asymptomatic recurrences detected by CEA permit curative resection in 17.8% of cases versus only 3.1% when recurrence is symptom-detected—a six-fold difference. 2, 3
• Intensive follow-up combining CEA monitoring with CT imaging reduces overall mortality (p=0.002) and improves 5-year survival from 63.7% to 72.1% (p=0.0001). 1, 2

Sensitivity and Specificity

Performance Characteristics

• Sensitivity for detecting recurrence ranges from 50–80%, with specificity and negative predictive value above 80%. 6
• CEA is most sensitive for hepatic metastases (73.3%) and relatively insensitive for local, pulmonary, or peritoneal involvement. 7, 8
• False-positive rate: 7–16%; false-negative rate: approximately 40%. 2

Integration with Other Surveillance Modalities

Imaging Requirements

• CEA monitoring must be combined with contrast-enhanced CT of chest, abdomen, and pelvis every 6–12 months for the first 3 years, as 26.5% of asymptomatic recurrences identified by CT are surgically resectable even when CEA is normal. 3
• Colonoscopy at 1 year post-resection, then every 3–5 years depending on findings. 1, 2

Trend Analysis

• Serial CEA measurements have better diagnostic accuracy than isolated elevations; persistently rising values above baseline strongly suggest disease progression. 1

Common Pitfalls

• Do not extend intensive CEA surveillance beyond 5 years for most patients, as incremental benefit is negligible. 2
• Do not rely on CEA alone for clinical decision-making; confirm any rise with imaging before initiating therapy. 2
• Do not interpret CEA elevation during the first 4–6 weeks of new chemotherapy as definitive progression, particularly with oxaliplatin-based regimens. 1, 2
• Do not assume a normal pre-operative CEA eliminates the need for post-operative monitoring, as 44% of patients with normal baseline CEA will develop elevation at recurrence. 2

Other Malignancies

Breast Cancer

• CEA is elevated in 50–60% of patients with metastatic breast cancer and can be used for monitoring during active therapy in conjunction with imaging. 1

Other Cancers

• CEA is elevated in approximately 30% of cholangiocarcinoma cases and in mucinous ovarian carcinoma (use CA-125/CEA ratio <25:1 to differentiate primary ovarian from gastrointestinal metastases). 1